Selected research
Industry Research
Adeno-Associated Virus (AAV) Gene Therapy Industry Research Report 2026
Market perspective
The global Adeno-Associated Virus (AAV) Gene Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Adeno-Associated Virus (AAV) Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Adeno-Associated Virus (AAV) Gene Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Adeno-Associated Virus (AAV) Gene Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Adeno-Associated Virus (AAV) Gene Therapy include AGC Biologics, StrideBio, SIRION Biotech, Neurophth Biotechnology, Belief BioMed, BiBo Biopharma Engineering Co., LTD., Beihai Kangcheng, PackGene Biotech and Sarepta Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Adeno-Associated Virus (AAV) Gene Therapy market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Adeno-Associated Virus (AAV) Gene Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Adeno-Associated Virus (AAV) Gene Therapy Market by Company
AGC Biologics
StrideBio
SIRION Biotech
Neurophth Biotechnology
Belief BioMed
BiBo Biopharma Engineering Co., LTD.
Beihai Kangcheng
PackGene Biotech
Sarepta Therapeutics
Carbon BioSciences
Kelonia Therapeutics
Roche
Remedium Bio
Creative Biolabs
Affinia Therapeutics
Spark Therapeutics
Adeno-Associated Virus (AAV) Gene Therapy Segment by Type
Luxturna
Zolgensma
Others
Adeno-Associated Virus (AAV) Gene Therapy Segment by Application
Central Nervous System Diseases
Ocular Diseases
Liver-directed Diseases
Other Hereditary Diseases
Adeno-Associated Virus (AAV) Gene Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adeno-Associated Virus (AAV) Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Adeno-Associated Virus (AAV) Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adeno-Associated Virus (AAV) Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Adeno-Associated Virus (AAV) Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Luxturna
- Zolgensma
- Others
Applications
- Central Nervous System Diseases
- Ocular Diseases
- Liver-directed Diseases
- Other Hereditary Diseases
Companies covered
- AGC Biologics
- StrideBio
- SIRION Biotech
- Neurophth Biotechnology
- Belief BioMed
- BiBo Biopharma Engineering Co., LTD.
- Beihai Kangcheng
- PackGene Biotech
- Sarepta Therapeutics
- Carbon BioSciences
- Kelonia Therapeutics
- Roche
- Remedium Bio
- Creative Biolabs
- Affinia Therapeutics
- Spark Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Adeno-Associated Virus (AAV) Gene Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Luxturna
- 2.2.3 Zolgensma
- 2.2.4 Others
- 2.3 Adeno-Associated Virus (AAV) Gene Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Central Nervous System Diseases
- 2.3.3 Ocular Diseases
- 2.3.4 Liver-directed Diseases
- 2.3.5 Other Hereditary Diseases
- 2.4 Assumptions and Limitations
3 Adeno-Associated Virus (AAV) Gene Therapy Breakdown Data by Type
- 3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Adeno-Associated Virus (AAV) Gene Therapy Forecasted Market Size by Type (2027-2032)
4 Adeno-Associated Virus (AAV) Gene Therapy Breakdown Data by Application
- 4.1 Global Adeno-Associated Virus (AAV) Gene Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Adeno-Associated Virus (AAV) Gene Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Perspective (2021-2032)
- 5.2 Global Adeno-Associated Virus (AAV) Gene Therapy Growth Trends by Region
- 5.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Adeno-Associated Virus (AAV) Gene Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Adeno-Associated Virus (AAV) Gene Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Adeno-Associated Virus (AAV) Gene Therapy Market Dynamics
- 5.3.1 Adeno-Associated Virus (AAV) Gene Therapy Industry Trends
- 5.3.2 Adeno-Associated Virus (AAV) Gene Therapy Market Drivers
- 5.3.3 Adeno-Associated Virus (AAV) Gene Therapy Market Challenges
- 5.3.4 Adeno-Associated Virus (AAV) Gene Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Adeno-Associated Virus (AAV) Gene Therapy Players by Revenue
- 6.1.1 Global Top Adeno-Associated Virus (AAV) Gene Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Adeno-Associated Virus (AAV) Gene Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Adeno-Associated Virus (AAV) Gene Therapy Head Office and Area Served
- 6.4 Global Adeno-Associated Virus (AAV) Gene Therapy Players, Product Type & Application
- 6.5 Global Adeno-Associated Virus (AAV) Gene Therapy Manufacturers Established Date
- 6.6 Global Adeno-Associated Virus (AAV) Gene Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
- 7.2 North America Adeno-Associated Virus (AAV) Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
- 7.4 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
- 8.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
- 8.4 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
- 10.2 South America Adeno-Associated Virus (AAV) Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
- 10.4 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AGC Biologics
- 12.1.1 AGC Biologics Company Information
- 12.1.2 AGC Biologics Business Overview
- 12.1.3 AGC Biologics Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.1.4 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.1.5 AGC Biologics Recent Developments
- 12.2 StrideBio
- 12.2.1 StrideBio Company Information
- 12.2.2 StrideBio Business Overview
- 12.2.3 StrideBio Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.2.4 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.2.5 StrideBio Recent Developments
- 12.3 SIRION Biotech
- 12.3.1 SIRION Biotech Company Information
- 12.3.2 SIRION Biotech Business Overview
- 12.3.3 SIRION Biotech Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.3.4 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.3.5 SIRION Biotech Recent Developments
- 12.4 Neurophth Biotechnology
- 12.4.1 Neurophth Biotechnology Company Information
- 12.4.2 Neurophth Biotechnology Business Overview
- 12.4.3 Neurophth Biotechnology Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.4.4 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.4.5 Neurophth Biotechnology Recent Developments
- 12.5 Belief BioMed
- 12.5.1 Belief BioMed Company Information
- 12.5.2 Belief BioMed Business Overview
- 12.5.3 Belief BioMed Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.5.4 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.5.5 Belief BioMed Recent Developments
- 12.6 BiBo Biopharma Engineering Co., LTD.
- 12.6.1 BiBo Biopharma Engineering Co., LTD. Company Information
- 12.6.2 BiBo Biopharma Engineering Co., LTD. Business Overview
- 12.6.3 BiBo Biopharma Engineering Co., LTD. Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.6.4 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.6.5 BiBo Biopharma Engineering Co., LTD. Recent Developments
- 12.7 Beihai Kangcheng
- 12.7.1 Beihai Kangcheng Company Information
- 12.7.2 Beihai Kangcheng Business Overview
- 12.7.3 Beihai Kangcheng Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.7.4 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.7.5 Beihai Kangcheng Recent Developments
- 12.8 PackGene Biotech
- 12.8.1 PackGene Biotech Company Information
- 12.8.2 PackGene Biotech Business Overview
- 12.8.3 PackGene Biotech Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.8.4 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.8.5 PackGene Biotech Recent Developments
- 12.9 Sarepta Therapeutics
- 12.9.1 Sarepta Therapeutics Company Information
- 12.9.2 Sarepta Therapeutics Business Overview
- 12.9.3 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.9.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.9.5 Sarepta Therapeutics Recent Developments
- 12.10 Carbon BioSciences
- 12.10.1 Carbon BioSciences Company Information
- 12.10.2 Carbon BioSciences Business Overview
- 12.10.3 Carbon BioSciences Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.10.4 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.10.5 Carbon BioSciences Recent Developments
- 12.11 Kelonia Therapeutics
- 12.11.1 Kelonia Therapeutics Company Information
- 12.11.2 Kelonia Therapeutics Business Overview
- 12.11.3 Kelonia Therapeutics Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.11.4 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.11.5 Kelonia Therapeutics Recent Developments
- 12.12 Roche
- 12.12.1 Roche Company Information
- 12.12.2 Roche Business Overview
- 12.12.3 Roche Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.12.4 Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.12.5 Roche Recent Developments
- 12.13 Remedium Bio
- 12.13.1 Remedium Bio Company Information
- 12.13.2 Remedium Bio Business Overview
- 12.13.3 Remedium Bio Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.13.4 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.13.5 Remedium Bio Recent Developments
- 12.14 Creative Biolabs
- 12.14.1 Creative Biolabs Company Information
- 12.14.2 Creative Biolabs Business Overview
- 12.14.3 Creative Biolabs Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.14.4 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.14.5 Creative Biolabs Recent Developments
- 12.15 Affinia Therapeutics
- 12.15.1 Affinia Therapeutics Company Information
- 12.15.2 Affinia Therapeutics Business Overview
- 12.15.3 Affinia Therapeutics Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.15.4 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.15.5 Affinia Therapeutics Recent Developments
- 12.16 Spark Therapeutics
- 12.16.1 Spark Therapeutics Company Information
- 12.16.2 Spark Therapeutics Business Overview
- 12.16.3 Spark Therapeutics Revenue in Adeno-Associated Virus (AAV) Gene Therapy Business (2021-2026)
- 12.16.4 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
- 12.16.5 Spark Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst